Recombinant Mouse Glutaminyl-peptide cyclotransferase-like protein (Qpctl)

Basic Research Questions

• What is the primary biochemical function of QPCTL in mouse models?

QPCTL catalyzes the formation of pyroglutamate residues at the NH2-terminus of proteins, thereby influencing their biological properties . This enzymatic activity is particularly important for:

• Formation of the high-affinity SIRPα binding site on the CD47 "don't-eat-me" protein

• Protection of monocyte chemoattractant proteins (MCPs) like CCL2 and CCL7 from DPP4-mediated truncation

• Enhancement of chemokine stability and signaling capacity in vivo

The pyroglutamate modification increases chemokine resistance to aminopeptidases and enhances receptor signaling, as demonstrated with CCL2 and CX3CL1 .

• What methodologies are effective for generating QPCTL-knockout mouse models?

QPCTL-deficient (QPCTL−/−) mouse models can be generated using CRISPR/Cas9 gene editing with the following protocol :

This approach generates viable QPCTL-deficient mice on the C57BL/6JRj background that can be used for tumor challenge studies and other experiments .

• How can I verify functional QPCTL knockout in experimental models?

Functional verification of QPCTL knockout can be conducted through multiple complementary methods :

• SIRPα binding assay: Stain peripheral blood cells with mouse SIRPα and an anti-mouse CD47 antibody that recognizes CD47 independent of pyroglutamate formation. QPCTL−/− mice display significantly decreased SIRPα binding compared to wild-type littermates .

• Chemokine modification analysis: Measure levels of pyroglutamate-modified chemokines (e.g., pE-CCL7) in serum using specific antibodies. QPCTL−/− mice show significantly reduced pE-CCL7 levels regardless of DPP4 activity .

• Sequence validation: Perform sequence analysis of the relevant gene locus by TIDE analysis to confirm genomic disruption .

• Phenotypic verification: Observe reduced circulating and splenic monocyte counts in QPCTL−/− mice, similar to the phenotype in mice lacking Ccr2, Ccl2, or Ccl7 expression .

• What cell lines are appropriate for studying QPCTL function in tumor models?

Several mouse tumor cell lines have proven suitable for QPCTL research :

These cell lines can be effectively modified using CRISPR/Cas9 technology to create QPCTL-deficient variants for comparative studies .

Advanced Research Questions

• How does QPCTL deficiency alter the tumor microenvironment (TME)?

QPCTL deficiency induces multiple changes in the TME that collectively promote anti-tumor immunity :

These changes collectively convert the TME to a pro-inflammatory environment that sensitizes tumors to immune checkpoint blockade therapy, particularly anti-PD-L1 treatment .

• What is the specific protocol for generating QPCTL-knockout cell lines?

QPCTL-knockout (KO) cell lines can be generated using the following CRISPR/Cas9 protocol :

Method 1: Transfection-based approach

• Transfect cells with pLentiCRISPR v.2 vector encoding sgRNA targeting murine QPCTL (5'-TATTGATTGTGCGACCCCCG-3')

• Supplement culture medium with 2 μg/ml puromycin for at least 2 days

• Sort selected cells based on αmCD47-MIAP301^hi^ mSIRPα-Fc^lo^ phenotype

• Isolate and expand single cells, then pool approximately 50 knockout clones

Method 2: Transduction-based approach

• Transduce cells with pLentiCRISPR v.2 vector encoding sgRNA targeting murine QPCTL

• Supplement culture medium with 2 μg/ml puromycin for at least 4 days

• Isolate and expand single cells, then pool 12 knockout clones

Validation of knockout can be performed by sequence analysis of the gene locus by TIDE analysis and by flow cytometry for SIRPα binding capacity .

• What is the molecular mechanism by which QPCTL regulates monocyte homeostasis?

QPCTL regulates monocyte homeostasis through a precise molecular mechanism involving chemokine modification :

• QPCTL catalyzes the formation of pyroglutamate residues (pE) at the N-terminus of monocyte chemoattractant proteins (MCPs), including CCL2 and CCL7

• This modification protects MCPs from DPP4-mediated N-terminal truncation, which would otherwise inactivate them

• The pE-modified chemokines show enhanced receptor signaling capacity and increased resistance to proteolytic degradation

• In QPCTL−/− mice, MCPs remain unmodified and susceptible to DPP4 degradation

• The resulting loss of functional chemokines disrupts monocyte mobilization from bone marrow to circulation

This mechanism is specific to QPCTL, as studies with QPCT−/−QPCTL−/− double knockout mice demonstrate that QPCT cannot compensate for QPCTL loss in MCP modification .

• How does QPCTL deficiency impact response to immunotherapy?

QPCTL deficiency significantly enhances response to immunotherapy through multiple mechanisms :

These findings provide a strong rationale for developing strategies to inhibit QPCTL activity as a means to enhance the efficacy of immune checkpoint inhibitors in cancer treatment .

• What experimental approaches can assess QPCTL's role in chemokine function?

Several experimental approaches can effectively evaluate QPCTL's impact on chemokine function :

In vitro assays:

• Recombinant protein production: Generate Q-CCL7, pE-CCL7, and truncated CCL7 for comparative studies

• Chemokine modification analysis: Measure formation of pyroglutamate-modified chemokines using specific antibodies

• Receptor signaling assays: Assess CCR2 activation by different chemokine forms

In vivo models:

• Intraperitoneal inflammation model: Inject various forms of recombinant chemokines and measure monocyte recruitment to peritoneal cavity

• DPP4 inhibition studies: Treat QPCTL−/− mice with DPP4 inhibitors to rescue monocyte mobilization

• Genetic approach: Cross QPCTL−/− and DPP4−/− mouse strains to analyze the interplay between these enzymes

Tumor models:

• Syngeneic tumor challenges in QPCTL−/− mice with wild-type or QPCTL-deficient tumor cells

• Single-cell RNA sequencing to characterize myeloid populations in the TME

• Flow cytometric analysis of tumor-infiltrating immune cells

These approaches provide complementary insights into QPCTL's role in chemokine function and immune cell recruitment .

• How do QPCTL and CD47 interact to regulate phagocytosis in the tumor microenvironment?

The QPCTL-CD47 interaction represents a critical regulatory axis for phagocytosis in the tumor context :

• QPCTL catalyzes the formation of pyroglutamate residues at the NH2-terminus of CD47, creating the high-affinity binding site for SIRPα

• This modification is essential for CD47 to function as an effective "don't-eat-me" signal that prevents macrophage-mediated phagocytosis

• In QPCTL−/− mice, blood cells display significantly decreased SIRPα binding compared to wild-type littermates, confirming QPCTL's critical role as a CD47 modifier in vivo

• The impaired CD47-SIRPα interaction in the absence of QPCTL likely contributes to enhanced phagocytic activity in the tumor microenvironment

• Interference with QPCTL activity, and hence CD47 maturation, represents a potential therapeutic strategy to promote anti-tumor immunity by enhancing phagocytosis of tumor cells

This mechanism provides an additional explanation for why QPCTL deficiency can enhance anti-tumor immune responses beyond its effects on chemokine regulation.

• What are the limitations of current QPCTL research models?

Current QPCTL research models have several important limitations to consider :

• Developmental effects: Germline deletion of QPCTL may lead to developmental alterations that influence the host's response to tumor challenge, potentially affecting the differentiation capacity of certain CAF or immune subsets independent of QPCTL activity during tumor outgrowth .

• Model specificity: Available glutaminyl cyclase inhibitors likely inhibit both QPCTL and QPCT due to the similarity of their active sites, making it difficult to distinguish between the effects of QPCTL versus QPCT inhibition .

• Translational gaps: While mouse models demonstrate QPCTL's role in regulating the TME, translating these findings to human cancers requires further validation.

• Temporal dynamics: Current models provide limited information about the temporal dynamics of QPCTL's effects on immune cell recruitment and function during tumor progression.

• Substrate identification: Around 600 human proteins harbor an N-terminal glutamine or glutamic acid residue after predicted signal peptide cleavage, suggesting many additional QPCTL substrates may exist beyond those currently identified .

Understanding these limitations is crucial for interpreting experimental results and designing future studies to address existing knowledge gaps.